Revolution Medicines breaks ground in challenging pancreatic cancer with two RAS drugs

In an interview Friday, Revolution Medicines CEO Mark Goldsmith, who says he prefers to understate rather than exaggerate, floated a lofty goal: cure pancreatic cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Bristol Myers makes a $4.8B bet on KRAS, striking deal to acquire Mirati

Bristol Myers Squibb has signed a $4.8 billion deal to buy Mirati Therapeutics and its cancer drug Krazati, which targets what was once thought to

October 9, 2023

Masimo wins de novo authorization for measure of high blood oxygen levels

Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Masimo has received de novo

October 16, 2023

Bicycle Therapeutics Plc Patent: High Affinity Nectin-4 Binders for Disease Treatment

Share this article According to GlobalData’s company profile on Bicycle Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Bicycle Therapeutics‘s grant

April 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.